<mq class="altjt"></mq>
万利国际
Promote a healthier life
for humankind through
advancements in science
Science-based
Benefit the patients with
high-quality medication as
we determined to innovate
Innovation-driven
Build a leading global
biopharmaceutical group
to serve more
Going Global
Fulfill social responsibilities
through accountable actions
Embrace Social
Responsibilities
Explore who we are
About us
Innovation is the core of our development strategy
Partnering
We are actively looking for synergistic partnerships
Walk into Hengrui
Est.
1970
New Molecular Entity drugs marketed in China
24
Other innovative drugs marketed in China
5
SH 600276
HK 1276
Est.
1970
Marketed Innovative Products in China
8
Partnered Innovative Product Launched
1
SH 600276
HK 1276
Pipeline
Our innovative pipeline covers the most of major therapeutic areas and continues to grow
Pipeline
Our innovative pipeline covers the most of major therapeutic areas and continues to grow
Investor
Enhance communication between our company and investors
Media
Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power
Media
Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)
Media
Hengrui Pharma and Braveheart Bio Enter Exclusive License Agreement for Cardiac Myosin Inhibitor HRS-1893